COVAX Facility

Gavi is co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.

Learn more

Latest COVAX news

18 October 2021

First Portuguese COVAX doses reach Senegal

As part of a pledge to share at least 5% of domestic supply of vaccines with its development partners, the first doses donated by Portugal through COVAX have reached Senegal.

11 October 2021

Vigne des Nations: 2020 vintage awarded to Gavi by Geneva Canton, for its action for global health

This Monday morning, 11 October, Mr Serge Dal Busco, President of the Council of State of Geneva, symbolically awarded the parcel of the Vigne des Nations to Gavi, the Vaccine Alliance. This recognition honours the commitment of this organisation…

11 October 2021

First Swiss-donated doses ship to Sierra Leone, as part of 4 million dose pledge

The first shipment of a Swiss donation of 4 million doses has arrived in Sierra Leone, with 24,000 doses of the AstraZeneca vaccine touching down in Freetown on 9 October 2021.

6 October 2021

Gulf countries unite to support COVAX

Gulf Cooperation Council (GCC) countries have come together to support global equitable access to COVID-19 vaccines, with pledges now totalling US$ 221 million in funding pledges and US$ 50 million in in-kind support from all six Member States,…

29 September 2021

Gavi Board meets to discuss routine immunisation, COVAX’s 2022 strategy

The Gavi Board met yesterday to discuss the impact of the pandemic on routine immunisation and how COVAX can best support countries’ efforts to control the pandemic, as part of a broader consultative process to develop the 2022 COVAX strategy

23 September 2021

Global leaders commit further support for global equitable access to COVID-19 vaccines and COVAX

Leaders pledge financing, dose donations, support for country readiness and delivery and scale up of global manufacturing, to enable equitable access to COVID-19 vaccines.

22 September 2021

DFC and Citi Risk Management Solution Helps Gavi Strengthen the Foundations of the COVAX Facility

U.S. International Development Finance Corporation, in conjunction with Citi, launch risk management solution for COVAX Facility.

20 September 2021

Iceland renews commitment to global equitable access to vaccines: first doses arrive in Côte d’Ivoire

As part of a donation of 125,726 doses to COVAX, the first shipment of 35,700 doses of the AstraZeneca vaccine donated by Iceland has arrived in Côte d’Ivoire.

13 September 2021

Iraq receives first doses donated by Italy through COVAX

As part of its pledge to deliver 15 million doses of COVID-19 vaccines, the first doses donated by Italy have been delivered to Iraq, with more shipping to additional countries in the coming days.

8 September 2021

First delivery of German-donated COVID vaccines to COVAX land in Mauritania, with other deliveries to follow

Building on its pledge of EUR 1.62 billion to COVAX, the German government has donated the first batch of its pledge of 100 million doses of COVID-19 vaccines, the majority of which will be delivered via COVAX. 

8 September 2021

Joint COVAX statement on Supply Forecast for 2021 and early 2022

COVAX has already achieved significant progress: more than US$10 billion has been raised; legally-binding commitments for up to 4.5 billion doses of vaccine; 240 million doses have been delivered to 139 countries in just six months.

6 September 2021

First doses donated by Belgium through COVAX arrive to Armenia

As part of its pledge to deliver 4 million doses of COVID-19 vaccines, the first doses donated by Belgium have been delivered to Armenia.

2 September 2021

Canada donates doses through COVAX – Nigeria, Kenya and Niger to receive first doses

Three countries in Africa will receive the first Canadian-donated doses of the AstraZeneca vaccine – Nigeria (801,600 doses), Kenya (459,300) and Niger (100,800) – as part of an overall Canadian pledge of over 40 million doses to COVAX

30 August 2021

France donates 10 million doses to Africa through COVAX and AU

African Union Member States are to receive an additional 10 million doses of Astra Zeneca and Pfizer COVID-19 vaccines through COVAX and the Africa Vaccine Acquisition Trust (AVAT), thanks to a new arrangement with the French government and the…

26 August 2021

First Danish doses delivered through COVAX arrive in Algeria

The first deliveries from a pledge of 1 million doses to be donated to COVAX by Denmark have arrived, with 57,600 doses of the AstraZeneca (AZ) vaccine to Algeria on 26 August.

13 August 2021

UK-donated COVID-19 vaccine doses reach African countries

The first AstraZeneca doses donated to COVAX by the United Kingdom (UK) will soon arrive in Angola, Egypt, Ethiopia, Ghana, Kenya, Malawi, Nigeria, Senegal and Uganda, with Zambia and DRC set to be the first to receive these UK-donated vaccines…

6 August 2021

China pledges US$ 100 million towards equitable access to COVID-19 vaccines for lower-income countries

The Government of the People’s Republic of China (China) has pledged US$100 million to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC). The announcement, made at the International Forum on COVID-19 Vaccine Cooperation, hosted by China,…

5 August 2021

First doses donated by Spain through COVAX arrive to Peru, Guatemala, Paraguay and Nicaragua

As part of its pledge to deliver 22.5 million doses of COVID-19 vaccines, the first doses donated by Spain are arriving to countries in Latin America.

4 August 2021

New financing agreement boost for malaria vaccine

Gavi, MedAccess and GlaxoSmithKline join forces to guarantee continued production of the RTS,S antigen for the RTS,S/AS01e malaria vaccine.

30 July 2021

First Swedish doses delivered through COVAX

As part of a pledge to deliver at least three million doses of COVID-19 vaccines, the first doses donated by Sweden have been delivered to countries this week, with shipments arriving in Kyrgyzstan and Afghanistan

30 July 2021

First deliveries of Norway-donated COVID-19 vaccines to COVAX

Norway donates first doses to COVAX, with first shipments arriving in Nicaragua and Uganda on 30 July. In total, Norway has pledged 5 million doses to COVAX, as well as US$ 141 million in funding.

26 July 2021

COVAX and World Bank to Accelerate Vaccine Access for Developing Countries

COVAX and the World Bank will accelerate COVID-19 vaccine supply for developing countries through a new financing mechanism that builds on Gavi’s newly designed AMC cost-sharing arrangement. This allows AMC countries to purchase doses beyond the…

23 July 2021

First doses donated by Japan to COVAX reach lower-income countries

The first COVID-19 vaccine doses donated by Japan to the Gavi COVAX Advance Market Commitment (Gavi COVAX AMC) have been shipped, with first shipments set to arrive in Cambodia and Iran on Friday, 23 July, and Bangladesh on Saturday, 24 July.

16 July 2021

US-donated vaccine deliveries to Africa set to begin, with first deliveries planned to Burkina Faso, Djibouti, and Ethiopia

16 July 2021 – Following close collaboration between the African Union (AU)/ African Vaccine Acquisition Trust (AVAT), COVAX and the United States Government, AU Member States are set to receive approximately 25 million COVID-19 vaccines to…

12 July 2021

Gavi signs agreements with Sinopharm and Sinovac for immediate supply to COVAX

Gavi, the Vaccine Alliance announced today that it had signed advance purchase agreements (APAs) with Sinopharm for its “BBIBP-CorV” inactivated virus vaccine against COVID-19 as well as with Sinovac for its inactivated virus vaccine against…

1 July 2021

Joint COVAX Statement on the equal recognition of vaccines

Geneva/New York/Oslo, 01 July 2021 – COVAX was built on the principle of equitable access to COVID-19 vaccines to protect the health of people all across the globe. That means protecting their lives and livelihoods, including their ability to…

30 June 2021

Gavi signs agreement with Clover Biopharmaceuticals for supply to COVAX

Geneva, 30 June 2021 – Gavi, the Vaccine Alliance announced today that it had signed an advance purchase agreement (APA) with Clover Biopharmaceuticals for its SCB-2019 protein-based adjuvanted vaccine candidate against COVID-19. The agreement…

27 June 2021

US-donated vaccine deliveries through COVAX set to begin, with first shipment to Honduras

Geneva, 27 June 2021 – Following announcements in recent weeks of donation pledges by the Biden-Harris Administration, COVAX is preparing to ship doses of COVID-19 vaccines donated to COVAX by the United States Government to protect at-risk…

23 June 2021

What does COVAX’s latest supply forecast tell us?

The forecast is encouraging given the supply disruptions COVAX and countries with bilateral deals are currently experiencing, and the general challenges manufacturers are experiencing as they ramp up supply at historic speed and scale.

18 June 2021

Republic of Korea pledges US$ 200 million to support lower-income economies through Gavi COVAX Advance Market Commitment

The Republic of Korea has announced a pledge of US$ 200 million to the Gavi COVAX Advance Commitment (Gavi COVAX AMC), with US$ 100 million to be provided in 2021 and an additional US$ 100 million to be provided in 2022

13 June 2021

G7 announces pledges of 870 million COVID-19 vaccine doses, of which at least half to be delivered by the end of 2021

COVAX welcomes dose sharing commitments for 870 million additional doses to support equitable access to vaccines in 2021 and 2022, with the aim to deliver at least half by the end of 2021.

10 June 2021

Gavi welcomes U.S. decision to procure 500 million vaccine doses to be delivered through COVAX

Geneva, 10 June 2021 – Gavi, the Vaccine Alliance, today welcomes the decision by the United States Government to procure 500 million COVID-19 vaccine doses on behalf of the COVAX Facility.

3 June 2021

Gavi welcomes U.S. allocation plan for vaccine dose-sharing – 19 million doses donated to COVAX in first tranche

Gavi, the Vaccine Alliance, welcomes the announcement by the United States Government of its strategy for global vaccine sharing, which sets out how it will provide at least 80 million doses of vaccines to the rest of the world – with the…

2 June 2021

World leaders unite to commit to global equitable access for COVID-19 vaccines

The Gavi COVAX AMC Summit “One World Protected” virtual event, hosted today by the Government of Japan and Gavi, the Vaccine Alliance, raised US$ 2.4 billion from nearly 40 donor governments, the private sector and foundations, exceeding the…

31 May 2021

New Zealand transfers vaccine doses to COVAX – 6 Pacific nations first to benefit

Responding to an urgent need for doses around the world, the Government of New Zealand has pledged to transfer 1.6 million doses allocated through COVAX to lower-income economies.

27 May 2021

Call to action to equip COVAX to deliver 2 billion doses in 2021

Countries that are advanced in their vaccination programmes are seeing cases of COVID-19 decline, hospitalisations decrease and early signs of some kind of normality resume. However, the global picture is far more concerning.

21 May 2021

Global leaders renew their commitment to address urgency of COVID-19 pandemic

At today’s Global Health Summit, hosted by the European Commission and Italy as chair of the G20, leaders pledged their support to the Gavi COVAX Advance Market Commitment (AMC).

21 May 2021

Gavi signs agreement with Johnson & Johnson for supply of its COVID-19 vaccine to COVAX

The signed advance purchase agreement (APA) is for a commitment to purchase 200 million doses of the Johnson & Johnson vaccine, with the goal of them being made available to the COVAX Facility in 2021.

18 May 2021

Go Give One campaign gives public the opportunity to support access to COVID-19 vaccines for lower-income countries

Individuals can now directly fund vaccines for lower-income countries via the Gavi COVAX AMC to help end the pandemic. The platform will give businesses a chance to match employee and customer contributions.

12 May 2021

Japan to host Gavi's COVAX Advance Market Commitment (AMC) Summit

Geneva, 12 May 2021 – The Government of Japan yesterday announced that it will host the virtual Gavi COVAX Advance Market Commitment (AMC) Summit on June 2nd 2021. The event, co-hosted by Japanese Prime Minister H.E.

10 May 2021

Corporations, charities and governments step up support for equitable COVID-19 vaccine access at Vax Live concert

The pledges were announced at Global Citizen’s Vax Live Concert on Saturday, co-hosted by Selena Gomez and featuring messages from Prince Harry, the Duke of Sussex, His Holiness Pope Francis and several Heads of State

6 May 2021

Gavi signs agreement with Novavax to secure doses on behalf of COVAX Facility

The signed advance purchase agreement (APA) is for a commitment to purchase 350 million doses of the Novavax vaccine candidate. Deliveries will commence in Q3 2021, upon regulatory approval.

3 May 2021

Gavi signs agreement with Moderna to secure doses on behalf of COVAX Facility

The signed advance purchase agreement (APA) is for up to 500 million doses of the COVID-19 vaccine manufactured by Moderna. Supply via the agreement will take place from the second half of 2021 through 2022, with options in place to address the…

26 April 2021

Immunization services begin slow recovery from COVID-19 disruptions, though millions of children remain at risk from deadly diseases

Geneva/New York, 26 April 2021 – While immunization services have started to recover from disruptions caused by COVID-19, millions of children remain vulnerable to deadly diseases, the World Health Organization (WHO), UNICEF and Gavi, the Vaccine…

23 April 2021

France makes important vaccine dose donation to COVAX

Today, to mark the first year of the creation of the Access to COVID-19 Tools (ACT) Accelerator, President Emmanuel Macron announced that France has begun sharing vaccine doses with COVAX, starting with a first batch of 105,600 doses – with 500,…

15 April 2021

Global leaders rally to accelerate access to COVID-19 vaccines for lower-income countries

The “One World Protected” Event, hosted today by the United States and Gavi, the Vaccine Alliance, launched a campaign to raise US$ 2 billion for the global fight against COVID-19.

8 April 2021

COVAX reaches over 100 economies, 42 days after first international delivery

The COVAX Facility has now delivered life-saving vaccines to over 100 economies since making its first international delivery to Ghana on February 24th.

31 March 2021

Gavi and Save the Children form global partnership to immunise zero-dose and vulnerable children

The partnership will focus on reaching children who are currently receiving no routine vaccines and marginalised communities in line with Gavi’s vision to ‘leave no-one behind with immunisation’.

29 March 2021

United States to host launch event for Gavi COVAX AMC 2021 investment opportunity

The virtual event will bring together world leaders, the private sector, civil society, and key technical partners to galvanize resources and commitment to the Gavi COVAX Advance Market Commitment (AMC).

25 March 2021

COVAX updates participants on delivery delays for vaccines from Serum Institute of India (SII) and AstraZeneca

The COVAX Facility has notified participating economies that deliveries of doses from the Serum Institute of India (SII) will be delayed in March and April.

2 March 2021

COVAX publishes first round of allocations

Geneva/Oslo/New York, 2 March 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organization (WHO), as co-leads of the COVAX initiative for equitable global access to COVID-…

1 March 2021

First COVID-19 COVAX vaccine doses administered in Africa

Today, the governments of Côte d’Ivoire and Ghana began COVID-19 vaccination campaigns aimed at protecting healthcare workers

24 February 2021

COVID-19 vaccine doses shipped by the COVAX Facility head to Ghana, marking beginning of global roll-out

COVAX announces 600,000 doses of the AstraZeneca/Oxford vaccine licensed to Serum Institute of India have arrived in Accra, Ghana; further deliveries to Abidjan, Cote d’Ivoire are expected this week.

22 February 2021

No-fault compensation programme for COVID-19 vaccines is a world first

New programme makes compensation available to eligible individuals in 92 low- and middle-income countries without need to resort to law courts.

19 February 2021

G7 backs Gavi's COVAX Advance Market Commitment to boost COVID-19 vaccines in world’s poorest countries

Today G7 leaders announced a doubling of funding for Gavi COVAX AMC to support lower-income economies obtain life-saving vaccines against COVID-19, ensuring greater equity in fighting to end the acute phase of the pandemic.

18 February 2021

Gavi signs memorandum of understanding with Novavax on behalf of COVAX Facility

The signed memorandum of understanding (MoU) between Gavi and Novavax is to make a cumulative volume of 1.1 billion doses of the Novavax vaccine candidate available to the COVAX Facility.

16 February 2021

COVAX Statement on WHO Emergency Use Listing for AstraZeneca/Oxford COVID-19 Vaccine

Geneva / New York / Oslo – 15 February 2021 The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance (Gavi) and the World Health Organisation (WHO), as co-leads of the COVAX initiative for equitable global access to…

8 February 2021

COVAX Statement on New Variants of SARS-CoV-2

The emergence of variants of SARS-CoV-2, the virus that causes COVID-19, serve as a powerful reminder that viruses by their very nature mutate, and that the scientific response may need to adapt if they are to remain effective against them.

3 February 2021

COVAX publishes first interim distribution forecast

Geneva/Oslo/New York, 3 February 2021 – The Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance and the World Health Organisation, as co-leads of the COVAX initiative for equitable global access to COVID-19 vaccines…

22 January 2021

COVAX announces new agreement, plans for first deliveries

COVAX announced the signing of an advance purchase agreement for up to 40 million doses of the Pfizer-BioNTech vaccine; rollout to commence with successful execution of supply agreements.

18 December 2020

COVAX announces additional deals to access promising COVID-19 vaccine candidates; plans global rollout starting Q1 2021

COVAX now has agreements in place to access nearly two billion doses of several promising vaccine candidates, and laid the groundwork for further doses to be secured through contributions from donors.

17 December 2020

Gavi Board approves new push to reach unvaccinated children worldwide

Gavi Board approves more than US$ 600 million in new funding to help accelerate efforts to reach ‘zero-dose’ and under-immunised children in the face of the COVID-19 pandemic.

15 December 2020

Team Europe contributes €500 million to COVAX initiative to provide one billion COVID-19 vaccine doses for low- and middle-income countries

High-risk and vulnerable groups and healthcare workers first in line for successful vaccine.

24 November 2020

Gavi and IOM join forces to improve immunisation coverage for migrants

Memorandum of understanding signed today will strengthen collaboration on vaccination efforts and related health services for migrants and forcibly displaced persons across the world

24 November 2020

Gavi statement on AstraZeneca/Oxford interim efficacy data

Geneva, 24 November 2020 – Gavi, the Vaccine Alliance, as co-lead of COVAX and administrator of the COVAX Facility, welcomes the release of interim efficacy data for the AstraZeneca/Oxford COVID-19 vaccine candidate.

13 November 2020

COVAX Facility convenes first meeting of COVAX AMC engagement group

The COVAX AMC Engagement Group, composed of Gavi COVAX AMC participants, donors, and other stakeholders, forms a key component of Facility governance.

13 November 2020

Over US$ 2 billion raised to support equitable access to COVID vaccines with additional US$ 5 billion needed in 2021

The European Commission, France, Spain, The Republic of Korea and the Bill & Melinda Gates Foundation pledge US$ 360 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)

3 November 2020

COVAX Facility convenes first meeting of COVAX Shareholders Council

The COVAX Shareholders Council, composed of all self-financing participants, forms a key component of Facility governance.

30 October 2020

COVAX welcomes appointment of civil society representatives

As part of the global response to the COVID-19 pandemic, COVAX – the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, co-led by Gavi, CEPI, and the WHO – welcomes the appointment of civil society organisation representatives to…

28 October 2020

Gavi signs statement of intent to procure 200 million doses of Sanofi-GSK COVID-19 vaccine candidate for the COVAX Facility

Gavi, the Vaccine Alliance announced today that it had signed a Statement of Intent with Sanofi and GSK to provide 200 million doses of the companies’ adjuvanted recombinant protein COVID-19 vaccine to the COVAX Facility.

8 October 2020

Japan pledges US$ 130 million to support global access to COVID-19 vaccines

Japanese Government pledges US$ 130 million in funding to the Gavi COVAX Advance Market Commitment (AMC), bringing the total raised to roughly US$ 1.8 billion.

6 October 2020

Countries pledge nearly US$ 1 billion to support equitable access to COVID-19 vaccines

The United Kingdom, Canada, Germany, Italy and Sweden pledge approximately US$ 960 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC)

1 October 2020

Gavi to provide US$ 150 million to support low- and middle-income countries’ readiness to deliver COVID-19 vaccines

The Gavi Board has approved the provision of US$ 150 million in initial funding to jumpstart support COVAX AMC-eligible countries’ readiness to deliver COVID-19 vaccines, in the form of planning, technical assistance and cold chain equipment

29 September 2020

New collaboration makes further 100 million doses of COVID-19 vaccine available to low- and middle-income countries

Collaboration among the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation will accelerate manufacturing and delivery of up to an additional 100 million doses of future vaccines, if proven to be…

21 September 2020

Boost for global response to COVID-19 as economies worldwide formally sign up to COVAX Facility

64 higher income economies have now joined the COVAX Facility, with a further 38 economies expected to sign in the coming days

28 August 2020

Australia commits AU$ 80 million to guarantee access to COVID-19 vaccines for all

The funding will support the Gavi COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations

24 August 2020

172 countries & multiple candidate vaccines engaged in COVID-19 Vaccine Global Access Facility

Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries

19 August 2020

Call for applications: COVAX seeks civil society representatives to contribute to ensuring equitable global access to COVID-19 vaccines

CSOs will play a vital role in the development and implementation of the COVAX initiative as well as the deployment of any successful vaccine through COVAX.

7 August 2020

Up to 100 million COVID-19 vaccine doses to be made available for low- and middle-income countries as early as 2021

New landmark collaboration between the Serum Institute of India (SII), Gavi, the Vaccine Alliance and the Bill & Melinda Gates Foundation to accelerate manufacturing and delivery of up to 100 million doses of future safe and effective COVID-…

31 July 2020

92 low- and middle-income economies eligible to get access to COVID-19 vaccines through Gavi COVAX AMC

Gavi Board agrees scope of COVAX Advance Market Commitment (AMC), which aims to secure doses of COVID-19 vaccines for 92 low- and middle-income countries and economies at the same time as wealthier nations.

15 July 2020

More than 150 countries engaged in COVID-19 vaccine global access facility

Seventy-five countries submit expressions of interest to COVAX Facility, joining up to 90 further countries which could be supported by the COVAX Advance Market Commitment (AMC)

3 July 2020

New private sector commitments to fund access to future COVID-19 vaccines announced at international pledging summit

Global technology company TransferWise and a donor which asked to remain anonymous made significant financial commitments to Gavi’s Advance Market Commitment for COVID-19 Vaccines (Gavi COVAX AMC)

26 June 2020

Gavi Board calls for global access to COVID-19 vaccines

Gavi Board shows support for continued work on COVAX Facility: a global, coordinated mechanism designed to ensure rapid and equitable access to safe and efficacious COVID-19 vaccines to as broad a global population as possible

4 June 2020

Gavi launches innovative financing mechanism for access to COVID-19 vaccines

Gavi Advance Market Commitment for COVID-19 Vaccines (Gavi Covax AMC) launched at Global Vaccine Summit 2020 draws strong support, early commitments from global leaders.

COVAX vaccine roll-out

>378 million COVAX vaccines shipped
OWP
144 participants

As of 20 Oct 2021

 

What is COVAX?

COVAX is the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator

The ACT Accelerator is a ground-breaking global collaboration to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines.

COVAX is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi and the World Health Organization (WHO), alongside key delivery partner UNICEF. Its aim is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world.

For any enquiries about the COVAX Facility, please contact covax@gavi.org.

 

COVAX Humanitarian Buffer

The Humanitarian Buffer is a mechanism established within the COVAX Facility to act as a measure of ‘last resort’ to ensure access to COVID-19 vaccines for high-risk and vulnerable populations in humanitarian settings. Populations of concern in humanitarian settings may include refugees, asylum seekers, stateless persons, internally displaced persons, minorities, populations in conflict settings or those affected by humanitarian emergencies, and vulnerable migrants irrespective of their legal status. Both COVAX Participants and humanitarian agencies can apply for Humanitarian Buffer doses.

 

N.B. While application review, approval, prioritisation and allocation will be undertaken on an ongoing basis by the IASC decision-making body, applicants are advised that shipment of doses is contingent on available supply and successful contracting with manufacturers:

  • Supply constraints affecting the COVAX Facility will also impact the availability of doses to the Humanitarian Buffer.

  • Shipments for humanitarian agencies, including UN organisations, Red Cross and Red Crescent, International and national non-governmental and civil society organisations, are subject to successful conclusion of contracts with manufacturers, including on indemnity and liability-related arrangements.

Applying for the COVAX Humanitarian Buffer

COVAX Humanitarian Buffer applications are for doses, devices and delivery funding, as required. For any questions, or to submit an application, please contact COVAX_Humanitarian_Buffer@gavi.org.

 

COVAX Facility Governance

Gavi, the Vaccine Alliance is the legal administrator of the COVAX Facility, and has overseen the establishment of the COVAX Facility Advance Market Commitment (AMC) Engagement Group - a governance body comprising economies that are eligible for COVID-19 vaccines through the Gavi COVAX AMC - and the COVAX Facility Shareholders Council - composed of self-financing participants.

COVAX Facility AMC Engagement Group

Mandate: Established by the Gavi Board to convene representatives from implementing countries, donors and other parties engaged in the financing and operation of the AMC portion of the Facility, with the aim of providing strategic guidance and advice to the Office of the COVAX Facility on the operational aspects of the COVAX Facility.

Membership: Open to all implementing countries, donors, other partners engaged in financing and operations of the AMC portion of the Facility. A representative from each of WHO, PAHO, UNICEF, the World Bank, and Civil Society has a permanent observer seat.

Meeting minutes

Co-Chairs

 

Karina Gould
Minister of International Development, Canada

 

 

Retno L.P. Marsudi
Minister for Foreign Affairs, Indonesia

 

 

Lia Tadesse
Minister of Health, Ethiopia

COVAX FACILITY SHAREHOLDERS COUNCIL

Mandate: Established by the Gavi Board to convene Self-Financing Participants (SFPs) of the COVAX Facility with the aim of providing strategic guidance and advice to the Office of the COVAX Facility on the operational aspects of the COVAX Facility. It receives regular updates from the Office of the COVAX Facility, including reports on allocation decisions and overall activities, and decisions or recommendations made by technical bodies (MSDC, Independent Product Group, Procurement Reference Group and Independent Allocation Validation Group) and the Board.

Membership: Open to all SFPs. A representative from each of WHO, PAHO, UNICEF, the World Bank, Civil Society and the AMC92 Group has a permanent observer seat.

Meeting minutes

Co-Chairs

 

Dr. Chrysoula Zacharopoulou
Member of the European Parliament

 

 

Dr. Fernando Ruiz
Minister of Health, Columbia

 

Why we need COVAX

Developing a vaccine against COVID-19 is the most pressing challenge of our time - and nobody wins the race until everyone wins.

The global pandemic has already caused the loss of hundreds of thousands of lives and disrupted the lives of billions more. As well as reducing the tragic loss of life and helping to get the pandemic under control, introduction of a vaccine will prevent the loss of US$ 375 billion to the global economy every month. Global equitable access to a vaccine, particularly protecting health care workers and those most-at-risk is the only way to mitigate the public health and economic impact of the pandemic.

What COVAX offers

Population Doses for at least 20% of countries' populations
Vial Diverse and actively managed portfolio of vaccines
Delivery Vaccines delivered as soon as they are available
Pandemic End the acute phase of the pandemic
Economie Rebuild economies

 

Gavi's role in COVAX

  • COVAX Facility

Gavi is coordinating the development and implementation of the COVAX Facility, the global procurement mechanism of COVAX. The COVAX Facility will make investments across a broad portfolio of promising vaccine candidates (including those being supported by CEPI) to make sure at-risk investment in manufacturing happens now. This means the COVAX Facility, by pooling purchasing power from all countries that participate, will have rapid access to doses of safe and effective vaccines as soon as they receive regulatory approval. Guided by an allocation framework being developed by WHO, the COVAX Facility will then equitably distribute these doses to help protect the most at-risk groups in all participating countries.

Gavi is coordinating the development and implementation of the COVAX AMC, the financing instrument that will support the participation of 92 lower-middle and low-income economies in the COVAX Facility. The COVAX AMC is critical to ensuring equitable access to COVID-19 vaccines, regardless of income level – and requires an urgent investment of US$ 2 billion, from sovereign donors, philanthropies and the private sector, by the end of 2020. The COVAX AMC and associated support to the eligible countries that apply will build on Gavi’s two decades of experience delivering life-saving vaccines to more than half of the world’s population, including in the hardest to reach communities.

  • Country readiness & delivery

Gavi is working with Alliance partners UNICEF and WHO to ensure that the infrastructure is in place, and the technical support available, to make sure COVID-19 vaccines can be safely delivered to all those who need them. Gavi is also part of the health systems work of the ACT-Accelerator effort, focusing on areas where it has expertise and experience, such as cold chain.

Learn more

 

Key COVAX articles

View more

21 October 2021

“A moment of immense pride and joy”: Anuradha Gupta’s eight reflections on India’s billionth COVID-19 vaccine dose

As India celebrated its one-billionth COVID-19 vaccination, #VaccinesWork caught up with Anuradha Gupta, Gavi’s Deputy CEO and an Indian public health veteran.

21 October 2021

Combining COVID-19 and routine vaccination: Nigeria implements a “whole family” approach

The whole family approach is helping Lagos State tackle multiple disease outbreaks and helping families lead healthier lives.

21 October 2021

A million a day: Pakistan’s COVID-19 vaccine campaign hits its stride

After a halting start to its immunisation campaign, Pakistan has shifted into high gear, now administering a million doses a day. #VaccinesWork spoke to national health leaders and spent a morning at a rural vaccination centre to find out what…

18 October 2021

Vaccines save Eswatini’s education system

The delivery of COVID-19 vaccines has brought hope for the country’s education system.

15 October 2021

Convincing nomadic populations to get the jab in Northern Kenya

For the Gosha community, vaccines are not only protecting them from COVID-19, but are also bringing development to their area.

14 October 2021

Delivering COVAX supplies during a supply chain crisis, the HOPE Consortium steps up support to UNICEF

First flight facilitated by the Hope Consortium touches down in Belgium with large delivery of ultra-cold chain freezers for onward shipment to 21 African countries.

 

COVAX Facility and COVAX AMC document library

Click below

COVAX documents

17 March 2021

COVAX Pillar: Structure and Principles

9 November 2020 (updated 17 March 2021)

Last updated: 20 Oct 2021

Subscribe to our newsletter